Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Will the biotech winter leave startups frozen?

Overvaluation, inflation, and hype cycles have all contributed to a decline in biotech investment over the past year. Despite the downturn, startups are still producing revolutionary medical advancements, particularly in the area of longevity. Garri believes the biotech industry will endure.

He joined his co-founder and managing partner Sergey Jakimov to share insights on the current state of biotech investing in a recent article from Labiotech.eu. Garri leads the LongeVC team to help its portfolio companies and the larger biotech sector flourish despite challenging times.

Read the complete article here.